All posts by medical

Revisiting the industrial revolution in scientific lasers – Laser Focus World

ALLAN ASHMEAD, STEVE BUTCHER, and MARCO ARRIGONI

Experience from decades of industrial laser applications, along with vertical integration leading to better components and materials, have enabled laser manufacturers to build scientific lasers with industrial reliability. At Coherent (Santa Clara, CA), investment in an immersive reliability concept called HALT/HASS long used in other reliability-critical industries has assisted in achieving this goal (HALT stands for highly accelerated life testing and HASS stands for highly accelerated stress screening). For example, in a 2014 Laser Focus Worldarticle entitled Ultrafast scientific lasers undergo an industrial revolution, Coherent noted that a one-box femtosecond oscillator was delivering levels of reliability that opened the path towards significant advances in data productivity.

Six years is a long time in a dynamic field like ultrafast lasers, so now seems like a reasonable time to assess if and how this industrial revolution has progressed, and more importantly, how it has impacted real scientific studies. This second article on the topic focuses on the more complex and challenging domain of femtosecond amplifiers.

For many years, titanium sapphire (Ti:sapphire) was the gain material of choice in virtually every ultrafast amplifier and oscillator. Today, however, ytterbium (Yb)-doped crystals or fibers are well-established alternatives to Ti:sapphire and complement its performance capabilities. Ytterbium has the advantages of being directly and efficiently pumped by laser diodes, resulting in a smaller quantum defect than Ti:sapphire. As a result, Yb lends itself to more-compact platforms.

From an applications viewpoint, the important differences are power, pulse energy, and repetition rates. Ti:sapphire amplifiers are unmatched in their ability to deliver high pulse energy. Coupled with the short pulses (less than 35 fs) of turnkey Ti:sapphire amplifiers, this translates into peak powers approaching the terawatt level. These amplifiers are therefore favored for applications requiring high fluence such as strong-field physics and high harmonic generation (HHG) for extreme ultraviolet (EUV) or attosecond-pulse generation.

The optimum performance of one-box Ti:sapphire amplifiers is at low repetition rates: 110 kHz. Ytterbium amplifiers, on the other hand, have lower pulse energy, but deliver much-higher average power (tens of watts) with extremely flexible repetition rates up to the megahertz regime. As a result, Yb amplifiers are optimum for applications requiring fast data collection with modest energy requirement (such as imaging and solid-state spectroscopy) or where high average power is critical (such as materials processing). Moreover, as a newer material, Yb amplifiers have more room for performance improvements.

This article will examine four applications, three scientific and one industrial, that highlight the impact of the industrial revolution on day-to-day performance, reliability, and productivityeither in terms of data or process throughput.

Ferroelectric materials and films can support a permanent electric dipole (meaning electrically polarized), which is why they are already widely used in electronic and photonic devices. However, more-detailed information is needed on films as thin as a few unit cells, as these could support higher density electronics and also offer the potential of custom (atomic-scale) novel ferroelectric heterostructures. A group led by Dr. Morgan Trassin and Prof. Manfred Fiebig at ETH Zurich (Switzerland) has been conducting the first in situ measurements of film polarity during the actual growth process performed by pulsed laser deposition with an excimer laser (Coherent LPX 220).

In any material where there is a break in symmetry and long-range order, irradiating with intense laser light can result in some second-harmonic generation (SHG). This effect has already been used in the past as a diagnostic with thicker ferroelectric samples. However, no one had previously demonstrated in situ harmonic generation (ISHG) during the film growth process.

SHG is highly sensitive to polarization, says Trassin. So, we reasoned that we could use the polarization dependence of the SHG signal to map the alignment of domains in a ferroelectric film. And, more importantly, we wanted to investigate the potential of ISHG to follow the polarization (or depolarization) of ultrathin films during the epitaxial deposition process. The light source for their SHG setup is a Ti:sapphire one-box amplifier (Coherent Astrella) that pumps a tunable optical parametric amplifier (OPA).

The technique has proved successful and has been capable of measuring ferroelectric polarization properties, as films are grown from zero to just a few unit cells in thickness. Based on this success, the Trassin group has applied this technique to examine the local polarization orientation, as the layers are incorporated into heterostructure model devices.

What is the impact of industrial reliability? The stability of this amplifier to changes in ambient temperature is particularly important to our work, says Trassin. We grow these films in a deposition chamber with internal temperatures up to 950C, so the temperature of our lab unavoidably varies considerably during the day (see Fig. 1). But critical amplifier output (pointing and power) parameters are thankfully unaffected.

2D spectroscopy involves measuring an optical signal as a function of pulses with two different optical frequencies and provides a wealth of data that would be impossible to obtain by any other method. The signal can be based on various different processes, including absorption, Raman, and sum/difference frequency generation. The data can be presented as two-dimensional contour graphs plotted against two frequencies, but are usually recorded as time-domain data and then Fourier-transformed in the frequency space. To ensure coherence, the three (or four) different femtosecond pulses required for these measurements are generated from a single source using a pulse shaper in what is essentially a four-wave mixing effect in the sample. The very wide spectral bandwidth of the short Ti:sapphire pulses critically enables a wide frequency range to be covered in a single set of data.

A group led by Professor Wei Xiong at the University of California, San Diego has recently used 2D spectroscopy to investigate a heterogeneous CO2 reduction catalyst, Re(diCN-bpy)(CO)3Cl, bound as a monolayer on gold surfaces. The researchers have performed experiments based on sum-frequency generation (SFG), a technique originally developed by Xiong as a graduate student in the lab of Martin Zanni. SFG vibrational signals are only generated at surfaces and phase interfaces. So, comparison with 2D spectra of the unbound catalyst (that is, in solution) enabled the Xiong group to reveal how the catalyst is bound to gold (see Fig. 2) and how its bond structure is impacted by this.FIGURE 2. Orientations of a catalyst on a gold surface determined from HD 2D SFG data and data from reflection-mode infrared spectroscopy is simulated using density functional theory (DFT). Orientation a is preferred. Blue lines represent directions of the vibrational modes.(Courtesy of Wei Xiong)

Xiong cites the operational simplicity of their one-box industrialized amplifier (Coherent Astrella) as a key benefit in these inherently challenging experiments. Just as important is the long-term stability: some of their time-resolved experiments (i.e., 3DSFG) require data runs in excess of 40 hours, during which the amplifier output must remain perfectly stable.

Two-photon microscopy and related techniques represent a major market segment for one-box oscillators, particularly in neuroscience, and now one-box Yb amplifiers are starting to enable new neuroscience applications. The main applications here are three-photon (3P) microscopy, photostimulation of groups of neurons, and photoablation of select neurons. These all require one or more of the main Yb amplifier advantages: long output wavelength, high repetition rate, and high average power. For example, high power is needed for two-photon photostimulation of hundreds of neurons using optogenetic expression. The power requirement stems from the large number of cells to be stimulated simultaneously, as well as system losses in spatial light modulators (SLMs).

Three-photon microscopy is a relatively new technique that depends on the simultaneous absorption of three photons, a low-probability event that therefore requires the high photon flux from an amplifier rather than an ultrafast oscillator. As a scanning-imaging application, high repetition rate is also necessary to acquire many pixels. Here, a Yb amplifier is usually combined with a tunable OPA to deliver high power in the 1.3 and 1.7 m wavelength windows that yield deeper penetration into brain and other scattering tissues.

Professor Raluca Niesner at the German Rheumatism Research Center (DFRZ; Berlin, Germany) recently used a Yb amplifier (Coherent Monaco) together with an OPA (Coherent Opera-F) to perform 3P imaging inside lymph nodes. These are densely packed with cells, which causes scattering issues for two-photon microscopy.

One of the targets of my research group is improved understanding of the rogue inflammatory response that results in rheumatoid arthritis in particular, and in chronic inflammatory diseases in general, says Niesner. Preliminary studies of mouse-limb lymph nodes by Dr. Rakhymzhan in Niesners laboratory indicate that 3P excitation can deliver a dramatic increase in deep imaging capabilities, specifically a greater-than 2X increase in maximum imaging depth for 3P vs. 2P under identical conditions. Figure 3 shows typical images.FIGURE 3. Murine lymph-node z stack images, where z = 300 m, are obtained using a Coherent Monaco Opera-F combination tuned to a wavelength of 1630 nm and a LaVision Trim Scope microscope. The red image is due to 3P excitation of tdTomato (a fluorescent protein) detected at 595 (20) nm (a), the white image is due to SHG signals from collagen fibers detected at 810 (45) nm (b), and the green signal originates from THG of lipid bilayers, lipids, or other anisotropic structures and was detected at 525 (25) nm (c). The composite image combines the tdTomato and SHG signals (d).

Surely nothing illustrates the success of the industrialization of scientific ultrafast lasers more than the use of the same laser in both scientific and industrial applications. Bringing the story full circle, a brief look is taken at an industrial application that illustrates both the flexibility of Yb amplifiers and the broad benefits of the industrial revolution approach to scientific and commercial applications.

Lasers with ultrashort pulse durations have long been used in micromachining (cutting, drilling, scribing, and so on) because the short pulse duration minimizes the heat-affected zone (HAZ)the extent of surrounding material that exhibits undesirable thermal damage such as melting/resolidification or microcracking. The HAZ is minimized when the pulse duration is short compared to the thermal diffusion time in the target material, so that most of the extra heat associated with the cutting or drilling process is carried away in the ejected debris before it has time to spread into the surrounding material.

Until recently, ultrashort-pulse (USP) industrial lasers have been mostly confined to the picosecond domain, limited by the bandwidth of the neodymium (Nd)-doped gain medium. However, for some applications, even the small HAZ from picosecond lasers was problematic, indicating a need for even shorter pulse durations. Unfortunately, femtosecond amplifiers based on Ti:sapphire do not have the requisite combination of high repetition rates and high average power. The advent of Yb femtosecond amplifiers with output powers up to 60 W has thus completely changed this situation. One of the first applications to benefit has been medical device fabrication.

A standout example can be found at Motion Dynamics (Fruitport, MI), a manufacturer of difficult subassemblies for the medical market such as steerable catheter products for neurovascular interventions. They use a four-axis cutting machine (Coherent StarCut Tube) equipped with a Monaco femtosecond amplifier rated at 60 W (see Fig. 4). Chris Witham, President of Motion Dynamics says, Our products require cutting and drilling a range of different metals, including gold, where surface roughness and edge quality are critical qualities. The femtosecond laser enables us to fabricate these components in a single step, typically with no polishing or other postprocessing required.FIGURE 4. An example of a wire/spring subassembly cut with a Yb femtosecond amplifier (Coherent Monaco).(Courtesy of Motion Dynamics)

The success of the industrial revolution in ultrafast science has been clearly demonstrated in these, and many other, representative applications that are critically enabled by the reliability and stability resulting from this design and manufacturing approach.

Allan Ashmead is VP of the Research Laser Systems business unit, Steve Butcher is director of marketing for the Scientific Market, and Marco Arrigoni is director of marketing for the Advanced Systems business unit, all at Coherent, Santa Clara, CA; e-mail: allan.ashmead@coherent.com;coherent.com.

Follow this link:
Revisiting the industrial revolution in scientific lasers - Laser Focus World

UO team will use zebrafish in new study of aquatic symbioses – AroundtheO

A UO-led team of researchers spanning physics, neuroscience, molecular biology, ecology and evolution will use a new $325,000 grant to examine aquatic symbioses the interactions between different animal species living together.

The project is funded by a 30-month award from the Gordon and Betty Moore Foundation and involves the study of zebrafish in controlled ecosystems.

The team will leverage decades worth of pioneering research at the UO involving zebrafish and explorations of the gut microbiome, in which vast numbers of microbes contribute to both health and disease in their hosts. UO has been a leader in zebrafish research since the 1960s, when the late biologist George Streisinger established zebrafish as an ideal model for studying human development and disease.

We aim to develop new tools for studying these symbioses throughout the entire lifespan of zebrafish, which serves as a model aquatic animal and a model for phenomena relevant to all vertebrates, including humans, said Raghuveer Parthasarathy, an Alec and Kay Keith Professor in the Department of Physics, a member of the UOs Institute of Molecular Biology and Materials Science Institute, and the principal investigator on the award.

The project builds on the successes of the zebrafish group here at the UO and it pushes it to the next frontier of trying to capture the whole lifespan of the animal and its ecosystem, Parthasarathy said.

Along with Parthasarathy, the team includes Karen Guillemin, Judith Eisen and Brendan Bohannan, all professors in the Department of Biology. Guillemin is a Philip H. Knight Chair and a member of the Institute of Molecular Biology. Eisen is a member of the Institute of Neuroscience. Bohannan, the James F. and Shirley K. Rippey Chair in Liberal Arts and Sciences, is a member of the Institute of Ecology and Evolution.

The team also includes John Rawls, a professor of molecular genetics and microbiology at Duke University and the director of the Duke Microbiome Center.

Part of the Moore Foundations Symbiosis in Aquatic Systems Initiative, the project will contribute to a larger effort to equip the scientific community with new genetic tools, cultivation methods and other infrastructure to improve experimental capabilities in aquatic symbiosis research over the coming decade. Increasingly, researchers are recognizing that symbiotic bacteria are critical components in the processes that sculpt the evolution, ecology, development and physiology of animals, yet remarkably little is known about exactly how those processes play out.

The four UO researchers have worked together on previous projects as part of the UOs interdisciplinary Microbial Ecology and Theory of Animals, a National Institutes of Health-funded Center of Excellence in Systems Biology. The center is funded by a $7.6 million grant and seeks to better understand the bacteria and other microorganisms that reside in the animal gut and influence many biological functions.

Building on their earlier work studying individual biological processes, the new research will explore the entire ecosystem and lifespan of zebrafish and consider food chains, population densities and other attributes. The project will serve as a bridge between more traditional model system research and field studies, opening up new frontiers in zebrafish research, Parthasarathy said.

The project involves three main areas. Investigators will:

Were hoping to learn how can we both predict and control ecosystem constituents, things like food and bacteria and how can that give us healthy organisms throughout their lifespan, Parthasarathy said. Our approach focuses especially on better understanding nutrition and on engineering new aquatic habitats that allow controlled investigation of symbiotic interactions. We want to watch and learn from the entire process.

The UO team will be building on a strong foundation of zebrafish research. That includes groundbreaking work by Eisen examining interactions between the nervous system, immune system and bacteria in the gut, and Guillemins innovative development of specialized sterile zebrafish that allow scientists to better determine the role microbes play as animals grow.

Bohannan has conducted important research on zebrafish, tracking them throughout their life cycle to see how diet, genetics and immune response affect their microbial diversity. And Parthasarathy has employed physics to better understand how gut microbes move and interact with each other, producing stunning, high-resolution, three-dimensional images and videos of gut bacteria in zebrafish using a technique known as light sheet microscopy.

Rawls, the biologist from Duke University, studies gut bacteria in zebrafish and their role in regulating digestive physiology, innate immunity and gut-brain communication.

I think (this research) may open up a lot of ecological questions, Parthasarathy said. If we succeed, we can expand our methods to other species such as plants and algae and explore their interactions. I think there is lots of potential for growth.

The project is the latest in a string of awards to UO researchers from the Moore Foundation. Earlier this year Eisen received a $2 million grant through the same symbiosis initiative to probe the relationship between symbiotic bacteria and neural development, using zebrafish as a model organism. In January, UO biologist Kelly Sutherland received a $1.1 million grant from the foundation funding her research examining the swimming mechanisms of gelatinous marine organisms.

These awards are a testament to the exceptional research being conducted at the University of Oregon, said Provost and Senior Vice President Patrick Phillips. We are grateful to the Gordon and Betty Moore Foundation for their generous support of our researchers and their investment in these innovative and impactful projects, which support the foundations critical mission of fostering pathbreaking scientific discovery and further the UOs commitment to enriching the human condition through creative inquiry and scientific discovery.

By Lewis Taylor, University Communications

Read more:
UO team will use zebrafish in new study of aquatic symbioses - AroundtheO

Antibody drugs could be key tools against Covid-19. But will they matter? – STAT

From the moment Covid-19 emerged as a threat, one approach to making drugs to treat or prevent the disease seemed to hold the most promise: Theyre known as monoclonal antibodies.

Now, scientists are on the brink of getting important data that may indicate whether these desperately needed therapies could be safe and effective. Clinical trials involving a pair of antibodies developed by Regeneron Pharmaceuticals will read out early results in September. A separate effort from Eli Lilly could yield data later in the fall.

Despite experts eagerness to see the data, however, there remains a debate over just how significant a role any antibody treatment might play in changing the course of the pandemic.

advertisement

A lot of smart people who understand immunology and virology think antibodies will work, said Robert Nelsen, an investor at ARCH Venture Partners who is invested in Vir Biotechnology, which will start tests of its own Covid-19 antibody study this month.

Scott Gottlieb, the former commissioner of the Food and Drug Administration, is less sure antibody treatments will be significant factors in bringing the pandemic under control. Even though the development efforts have been proceeding extraordinarily fast by normal standards, the U.S. has spent billions of dollars purchasing vaccines in advance, but has done far less to shore up capacity for antibody drugs.

advertisement

We may have missed a window to scale the manufacturing of antibody drugs that could have been an important bridge to a vaccine and a hedge in the event vaccines are delayed or dont work, Gottlieb, a fellow at the American Enterprise Institute and board member for Pfizer and other health care companies, told STAT. These drugs had the ability to perhaps meaningfully change the contours of this epidemic, and we just wont have enough doses to realize that goal.

Monoclonal antibodies are antibodies the kind that the body produces to neutralize invading viruses that have been genetically engineered into new medicines.

In 1975, two researchers, Georges J.F. Khler and Csar Milstein, developed the method for mass-producing them by fusing antibody-producing cells from mice with cancer cells. They shared the Nobel Prize in physiology or medicine in 1984. The first monoclonal antibody drug, for kidney transplant patients, was approved in 1986. Today, Humira, an antibody from AbbVie that treats a host of immune-related diseases, is the pharmaceutical industrys top-selling product, generating $15 billion in sales last year.

Regeneron has produced several monoclonal antibodies since being founded in 1988, including Praluent for high cholesterol, Libtayo for a type of cancer, and Dupixent for severe eczema. In 2014, the technology was also used to develop an effective treatment for Ebola.

As the Covid pandemic hit, Regenerons chief scientific officer, George Yancopoulos, assigned Christos Kyratsous, a confident, Porsche-driving scientist with a dry sense of humor, to lead a team that would search for an antibody. In early February, a non-infectious fragment of genetic code of the novel coronavirus arrived at the companys research laboratories in Tarrytown, N.Y., from China, and the company has used this starting material to produce hundreds of virus-neutralizing antibodies using genetically engineered mice, along with blood taken from survivors of Covid-19.

But getting antibodies into people has taken time. I tragically right now have a 91-year-old aunt whos trapped in a nursing home where right now theres a coronavirus outbreak, Yancopoulos said in April. And I just wish I could get them our [drug] today. Its just not ready.

Other companies are advancing their own efforts. For years, AbCellera, a Vancouver-based biotech, had been working with the National Institutes of Health and the U.S. Department of Defense to game out the response to future pandemics. In February, the NIHs National Institute of Allergy and Infectious Diseases sent the company a sample of blood from a patient who had recovered from Covid-19. AbCellera inserted the sample into a credit-card-sized device that isolates the B cells that make antibodies, and used it to find more than 550 antibodies that might work against the virus.

Adaptive Biotechnologies, AbbVie, and AstraZeneca have also rushed forward with their own antibody efforts.

Regenerons antibodies REGN10933 and REGN10987 both target the spike protein on the virus surface that helps it invade cells, but individually, each drug binds to the protein at a different, non-overlapping location. This cocktail approach aims to increase the chance that the virus can be neutralized without escaping. Its the same multidrug strategy used successfully to treat other viral diseases such as HIV and hepatitis C. Regeneron refers to the dual antibody regimen as REGN-COV2.

The first look at Regenerons data will provide results on the ability of REGN-COV2 to reduce the amount of SARS-CoV-2 virus in patients compared to placebo. Safety and other data will also be announced.

Outcomes data will come later. For the study of hospitalized Covid-19 patients, Regeneron hopes to show that the treatment can improve clinical status based on a seven-point scale ranging from hospital discharge to death. In between, the scoring system measures changes in the use of supplemental oxygen or mechanical ventilation. In the study of ambulatory Covid-19 patients, REGN-COV2 is designed to speed recovery and prevent the disease from getting worse. Unlike Regeneron, Eli Lilly and AbCellera have chosen not to use a cocktail approach, starting instead by testing a single antibody. Data from its study, however, being conducted with the NIH, arent expected to be released until October or November.

Reducing the theoretical risk of escape mutations has a real cost, and the real cost is manufacturing, meaning you will have less doses available, meaning fewer people will be treated in this critical time period, Lilly Chief Scientific Officer Daniel Skovronsky told STAT during a recent event. So my view is we go for a single antibody, which means that we can treat twice as many people if it works.

The Lilly antibody, called LY-CoV555, will be investigated in a placebo-controlled clinical trial of approximately 300 patients hospitalized with mild to moderate Covid-19. An initial efficacy assessment based on symptoms improvement, including the need for supplemental oxygen, will be conducted five days following the injections of LY-CoV555 or placebo. If these initial results show a benefit for the Lilly antibody, the study will be expanded to enroll another 700 patients, including people with severe cases of Covid-19.

Recently published animal data suggest these antibody treatments may work in humans. Monkeys exposed to SARS-CoV-2 followed one day later with injections of the Regeneron cocktail cleared the virus faster than monkeys treated with a placebo. Damage to the lungs, including cases of pneumonia, was reduced but not eliminated in the monkeys treated with the cocktail compared to the placebo group. The monkey study was released via a preprint server, meaning the data had not yet been peer-reviewed or published in a journal.

In a research note, SVB Leerink analyst Geoff Porges called the monkey data quite encouraging, but he also cautioned it may not be curative in humans on its own, citing the inconclusive pneumonia results and the challenge of treating patients early, before they might have symptoms.

If clinical development for the antibody cocktails is successful, we believe it would be most likely to complement the existing standard of care and antiviral therapies such as remdesivir, rather than displacing antivirals, said Porges.

Nelsen, the investor at ARCH Venture Partners, said: If you treat people who are very sick, you may not see anything. If you treat people earlier, you will probably see what you saw in the monkeys: a significant reduction in virus, which doesnt necessarily mean a reduction in morbidity and mortality, but it should. What you really want to do is prevent the progression of the disease.

Vir, the biotech firm that Nelsen backed, will start a clinical trial of its lead antibody candidate VIR-7831 later this month, seeking to show that it can prevent hospitalization due to Covid-19. A second antibody candidate, VIR-7832, will advance into a clinical trial later this year. Both drugs are designed to bind to a location on the spike protein that creates a high barrier to resistance. In preclinical studies, the antibodies also recruit immune cells to help kill other cells already infected by the virus, Vir said.

Similar to vaccines, antibody treatments are also being developed to prevent Covid-19 infection, particularly in people who are at high risk and who might have been exposed to the virus through close contact with an already infected person.

Once someone has come into contact with some of the disease, its too late for an active vaccine, Lillys Skovronsky said. But a passive immunization like our antibody could be valuable. When you think about the populations that are suffering the most, its the elderly, its the immunocompromised, its patients in nursing homes and long-term care facilities.

Lilly and NIAID are conducting a 2,400-patient Phase 3 study to test whether its treatment can keep nursing home patients from developing Covid-19. The antibody will be given to patients and staff at places where there has been an infection to see if it can stop them from developing the disease. To conduct the study, Lilly is deploying a fleet of recreational vehicles that can be used prepare study drug and do lab work, as well as pull trailers that can be used as on-site infusion clinics.

Regeneron and NIAID are also conducting a prevention study in 2,000 healthy adults who are household contacts with an individual with a positive Covid-19 test. Will it be possible to manufacture enough antibody? Regeneron said it is in active discussions with other parties that can add additional manufacturing capacity.

The big determinant of how fast answers will emerge will be the speed at which doctors can enroll patients in these studies, said Anita Kohli, the director of clinical research at Arizona Clinical Trials and an investigator for both Regeneron and Eli Lilly. This, she said, is harder than it sounds, especially for patients who are not so sick that they are in the hospital. I think some of the recruitment is more difficult, because youre recruiting sick people, she said. Sick people want to eat chicken soup and stay at home and not go to the clinical trials center.

One problem is that diagnostic tests are taking a long time to come back. Doctors are supposed to enroll patients in the studies within five or six days of the onset of symptoms. If testing takes two weeks to come back, patients often recover before they are enrolled. Kohlis center has begun to test patients for Covid in the hopes that some will volunteer to be in studies.

Vaccines are not going to work for everybody, she said. People are still going to get sick, theres no two ways about it. And weve got to have a treatment.

The problem, she said, is that patients are not being made aware of clinical trials for therapeutics soon enough.

People have not been directed toward clinical trials, or are not thinking about them, she said. I think thats what we need to change here. Its not that they arent very exciting, they are very exciting. They just arent talked about enough.

Original post:
Antibody drugs could be key tools against Covid-19. But will they matter? - STAT

Turning Heads: The Vanderbilt Brain Institute has emerged as a hub of discovery as neurosciences influence expands – Vanderbilt University News

Science Photo Library

The ancient Egyptians were the first to mention the brain in writingpreserved on a 2,700-year-old papyrus that details the symptoms of head injuriesbut the importance of the organ escaped them. They believed it was the heart, not the head, that controlled human thought and emotion.

Today our knowledge of the brain has far eclipsed what our forebears knew only a few generations ago, never mind 27 centuries. The burgeoning field of neuroscience has led to an almost unprecedented burst of scientific research, reshaping disciplines from biochemistry and personalized medicine to law, psychology and the arts. Meanwhile, newer imaging technologies, like functional magnetic resonance imaging (fMRI), have offered revolutionary ways to view brain activity in real time.

As a result of these and other breakthroughs, neuroscience has permeated our lives as never before. Yet, as researchers learn more about the brain, the more its mysteries grow in ways that dont lend themselves easily to a single discipline. Scientists have been unable to disentangle, for example, genetics and anatomy from human experience and emotion.

What is required instead is a closely collaborative, multidisciplinary approach to understanding the brain. For more than 20 years, Vanderbilt has done just that, leveraging its culture of collaboration to emerge as a leader in neuroscience research and education. Now, as our knowledge of neuro-everything continues to growaided by emerging technologies like artificial intelligence and data sciencethe university has reaffirmed its commitment to this important space.

Vanderbilt is on the leading edge of neuroscience discovery in research, education and training, says Provost and Vice Chancellor for Academic Affairs Susan R. Wente. You can see it in the breadth of our neuroscientists work, from their innovative use of scanning technology to better understand the brains many functions, to the advances theyve made in pharmacology and biochemistry as they pursue treatments for some of the worlds most vexing neurological disorders.

More important, though, you see it in how these scientists work together across their diverse fields, lending expertise and support to each others efforts, as they further our knowledge of the brain. Vanderbilts success in neuroscience ultimately depends on this teamwork.

At the center of this work is the Vanderbilt Brain Institute, a trans-institutional entity that oversees and facilitates neuroscience-related endeavors across the university and in partnership with Vanderbilt University Medical Center. The VBI recently marked its 20th anniversary, a span that has seen the institutes wide-ranging missionsincluding administering the universitys Neuroscience Graduate Program, as well as postdoctoral training and community outreachsteadily coalesce under a single umbrella.

Of those 20 years, the past two in particular have been among the most transformative for the VBI, as Vanderbilt has allocated new resources toward its continued expansion, including a reimagined physical home on campus. The university also has raised the institutes visibility by bringing in Lisa Monteggia, an esteemed researcher and educator from UT Southwestern Medical Center in Dallas, to lead it.

Hired in September 2018 as the VBIs Barlow Family Director following a nationwide search, Monteggia has begun implementing a forward-looking plan for the institute, making strategic decisions and investments that not only expand and enhance Vanderbilts neuroscience community and its collaborative spaces on campus but also harness the creative, cross-disciplinary synergy that naturally results from those efforts.

The idea is to take advantage of our strengths, including the incredible collegiality we have as a smaller university, as we continue to grow and build, says Monteggia, who is also a professor of pharmacology. Were hiring new faculty and also exploring different areas of collaboration, like connecting the arts with psychiatry, for example, or the biological sciences with education and engineering. Its really about building bridges that further our understanding of the brain.

Vanderbilts roots in neuroscience stretch back several decades before the launch of the VBI. For example, in the 1950s and 60s, developmental psychologist Susan Grays pioneering work helped George Peabody College for Teachers develop a national reputation for research on intellectual and developmental disabilities, leading to the launch in 1965 of what is today known as the Vanderbilt Kennedy Center for Research on Human Development. The VKC works to improve the lives of people with intellectual and developmental disabilities through research, education and advocacy.

By the 1970s there would be other key faculty additions, including the late psychology professor Oakley Ray, who introduced the academic focus of neuropharmacology, and Jon Kaas, the Gertrude Conaway Vanderbilt Distinguished Professor of Social and Natural Sciences.

Since his arrival at Vanderbilt in 1973, Kaas has seen the neuroscience landscape at the university grow significantly, thanks in part to his own numerous contributions to the field, including illuminating how sensory information is distributed and integrated in the brain. But Kaas is also quick to note the impact of other faculty who have brought neuroscience to the forefront at the university.

Among them was the late Vivien Casagrande, professor of cell and developmental biology, psychology, and ophthalmology and visual sciences, whom Kaas helped convince to come to Vanderbilt. Arriving on campus in 1975, she spent the next several decades expanding our knowledge of how the visual thalamus and cortex interact to construct our perceptual world.

Says Kaas, She was really the first faculty member trained as a neuroscientist to be hired at Vanderbilt.

Casagrande and Kaas were founding members of the Vanderbilt Vision Research Center (VVRC), launched in 1989 to enhance research and training in visual neuroscience in the Department of Psychology, Department of Ophthalmology and Visual Sciences, and others at the Medical Center. The concentration in vision science attracted other key faculty, including Randolph Blake, MA69, PhD72, Centennial Professor of Psychology and professor of ophthalmology and visual science, in 1988, and Jeffrey Schall, E. Bronson Ingram Professor of Neuroscience and professor of psychology and ophthalmology and visual sciences, in 1989.

Like Kaas, both are among the two dozen or so neuroscientists at Vanderbilt who have been elected fellows of the American Association for the Advancement of Science. Blake studies human visual perception, including binocular vision, motion perception and perceptual organization, while Schall investigates the neural and computational mechanisms of decision making.

Kaas also points to the hiring in 1991 of Ford Ebner, professor of psychology, emeritus, who has helped further our understanding of the brains plasticity (i.e., its ability to be molded and shaped by experiences), and his wife, Leslie Smith, principal senior lecturer of psychology. Vanderbilts first neuroscience Ph.D., in fact, was awarded to one of Ebners students. Kaas credits Smith, who previously had taught at Brown University, for elevating neuroscience education at Vanderbilt, particularly on the undergraduate side.

Leslie introduced the idea of a neuroscience major, and that really set things in motion, says Kaas of what is today the Interdisciplinary Program in Neuroscience for Undergraduates. The undergraduate program has fed into our graduate program and everything else that has come since.

Started in 1997, the undergraduate program, which is now administered by the VBI, is today the third largest major in the College of Arts and Science, with 355 students. Those who major in neuroscience typically go on to some of the countrys most competitive medical schools or graduate programs in neuroscience, biology or psychology.

Meanwhile, as the undergraduate program was getting off the ground, Elaine Sanders-Bush, PhD67, professor of pharmacology, emerita, led the launch of the Neuroscience Graduate Program and would go on to serve as its director until 2008. During that decade the program grew to more than 60 graduate students. Since then, it has evolved into the largest graduate program on campus with 109 training faculty and 82 current students.

The development of undergraduate and graduate programs in neuroscience was paralleled by the establishment of institutional research centers. The Center for Molecular Neuroscience, founded under direction of Randy Blakely in the School of Medicine, organized resources and motivated faculty hiring to investigate the cells and molecules of the brain. The complementary Center for Integrative and Cognitive Neuroscience, launched in 2000 under the direction of Jeffrey Schall, organized resources and motivated faculty hiring to investigate the circuits and functions of the brain.

The Vanderbilt Brain Institute was established to administer the graduate program and facilitate synergy of these centers with the VKC, VVRC and the involved departments. Sanders-Bush, whose research has contributed to our understanding of serotonin and its receptors, also served as the VBIs first director.

Coinciding with the launch of the VBI in 1999 were a couple of new faculty additionsIsabel Gauthier, David K. Wilson Professor of Psychology, and Ren Marois, professor and chair of the Department of Psychology and professor of radiology and radiological scienceswho would prove to have an important impact at Vanderbilt. Both had earned their Ph.D.s at Yale University andalong with Randolph Blake and Ford Ebnerwere early promoters of fMRI, Gauthier using it to explore visual object recognition and Marois to study the neural bases of attention and information processing.

Their move to Vanderbilt would help prompt their Yale mentor John Gore to follow them, bringing more than a dozen colleagues to establish the Vanderbilt University Institute of Imaging Science in 2002. Gore, the University Professor of Radiology and Radiological Sciences and holder of the Hertha Ramsey Cress Chair in Medicine, is known internationally for his pioneering work in biomedical imaging techniques.

During the past two decades, the university has become a magnet for other prominent neuroscientists, with a number of influential centers focused on brain research taking root, including the Warren Center for Neuroscience Drug Discovery and the Center for Cognitive Medicine.

As the VBI continued to evolve into a more cohesive framework, it got a champion in the form of Mark Wallace, an expert on multisensory processing who became director in 2008. Currently the dean of Vanderbilts Graduate School and holder of the Louise B. McGavock Chair, Wallace led the VBI to national prominence, spurring research while also bolstering its education initiatives, including helping launch the countrys first Ph.D. program in educational neuroscience at Peabody College in 2012.

Wallaces decision to step down from the VBIs directorship and become dean in 2016 provided an opportunity for Vanderbilt to refocus its approach to neuroscience. To aid in the search for Wallaces successor, David Barlow, the chairman and CEO of Psy Therapeutics, a Boston-based startup developing treatments for anxiety, depression and dementia, provided the gift to endow the Barlow Family Directorship, ensuring that the VBI would be able to recruit the best talent to that position in both the near and long term. (Among the members of Psy Therapeutics scientific advisory board is Dr. Sachin Patel, the James G. Blakemore Professor of Psychiatry, who studies cannabinoid neurobiology at Vanderbilt.)

While the VBI already had a solid foundation, there was a clear opportunity to grow the mission and expand, says Barlow, who got involved with Vanderbilt, including service on the Technology Transfer Advisory Committee, after his daughter Kelly Barlow, BA12, was a student. It was exciting to think about leveraging the ethos on campus and turning the institute into a hub that further facilitates interdisciplinary collaboration.

The VBI has a huge future ahead of it under Lisas leadership.

Coupled with the endowed directorship was a decision to move the VBI under the Office of the Provost. Aside from raising the institutes stature and visibility on campus, the move afforded a more direct line of communication with Wente, herself a pathbreaking scientist who was instrumental in convincing Monteggia to join Vanderbilts faculty.

Its unusual to have a provost with such a strong scientific background. She understands the importance of investing in the best science and has been incredibly supportive, Monteggia says. As a colleague reminded me before I took the job, there are very few opportunities like this that come along in any given professional career. The opportunity to lead and serve the VBI was simply too great to pass up.

Monteggias research focuses primarily on two areas. One is antidepressants and how they work, with the particular goal of developing more effective treatments for depressed individuals who have exhibited resistance to conventional drugs and are therefore more prone to suicide. The other area is the underlying causes of Rett syndrome, an autism spectrum disorder. While antidepressants and Rett syndrome may seem like two very distinct paths of inquiry, they overlap in one critical sense.

Certain neurodegenerative disorders, like Alzheimers, are characterized by loss of particular cells, Monteggia says. But there are other disorders like depression and autism that display no gross morphological anatomical changes in the brain. That suggests they are caused instead by functional changes at the level of how the neurons communicate. So we work backwards and look at a number of genes that are linked to these processes.

Finding common ground to explore these and other neuroscience questions is a key part of Monteggias vision for the VBI, and for her that begins quite literally with the physical location itself. Upon accepting the directorship, she worked with Wente to establish a better-defined home for the institute on the seventh and eighth floors of Medical Research Building III. The space now includes expanded offices and conference rooms, additional seating lounges, and a refurbished balcony area to host visiting luminaries in the field and other gatheringsall designed with the aim of fostering collaboration.

Were currently 109 faculty members split across 24 different departments, Monteggia says of the VBI. And neuroscience is also the largest graduate program on campus. So the idea is to have a place for them all to come. Its about bringing people together to talk about ideas, discuss projects, and just get to know each other.

As expansive as the VBI already is, Monteggia wants to continue growing the institute by working with deans on campus, particularly those at the College of Arts and Science, Peabody College, the School of Engineering, and the School of Medicines Basic Sciences, to make strategic faculty hires. And as part of that process and the VBIs other initiatives, she is ever mindful of the role that diversity and inclusion should play in that growth.

Im a firm believer that the more diversity we have, the better well be able to approach a problem and see it from different angles, she says.

Monteggia also recognizes that the VBIs role doesnt stop at the edge of campus. Its work can and should reverberate well beyond the classrooms and labs and into the wider community of Middle Tennessee, she says. This includes, among other things, having Vanderbilt students speak at local schools on neuroscience-related topics, collaborating with the Osher Lifelong Learning Institute on programming related to the aging brain, and organizing free public events and activities for Brain Awareness Month each March.

Ultimately, the VBIs work is part of a long continuum of efforts, now many centuries old, to demystify the brain and unwind its tangled secrets for the greater benefit of society. This endeavor has pushed our knowledge of neuroscience further than many ever could have predicted only a few generations ago, but there remains so much more we do not understand about the brain. And if the past is any indication, the more deeply we peer inside its folds, the more questions there likely will be.

As were going about this transformation, theres always an eye towards the future. I do have a vision for where were going, but Im trying to do it in a way that brings the most people together as possible, Monteggia says. Thats the only way well be able to answer these big questions facing science and society as a whole.

Seth Robertson is executive editor of Vanderbilt Magazine.

Read more:
Turning Heads: The Vanderbilt Brain Institute has emerged as a hub of discovery as neurosciences influence expands - Vanderbilt University News

What happens in the brain when we sleep? – Medical News Today

What occurs in the brain when we are deep in slumber? What are the different stages of sleep and what role do they play in learning and memory formation? What about in anxiety and pain? Do neurons and neurotransmitters also play a role? These are the questions we will tackle in this Special Feature, using the latest evidence available.

Scientists generally agree that there are four stages of sleep that we cycle through several times each night. The first three form the so-called non-rapid eye movement (REM) sleep and the fourth one is REM sleep where dreams occur.

In the first non-REM stage, the body and brain transition from wakefulness to sleep. The brain changes its electrical oscillations from the active, wakefulness pattern of brainwaves into a slower rhythm.

Muscle tone throughout the body relaxes. This is the phase during which our bodies may twitch as we enter slumber.

The second non-REM stage involves a drop in the bodys temperature, the heartbeat and breathing become slower, and the brainwaves slow down further. Short bursts of electrical activity in the brain may still characterize this stage of sleep.

The third stage of non-REM sleep is the deep sleep stage, which our bodies need to wake up feeling refreshed and restored. In this stage, heart rate, breathing, and brain activity all drop to their lowest point.

The REM, dream-filled light-sleep stage is the fourth and last one. According to the National Institute of Neurological Disorders and Stroke (NINDS), REM occurs about 90 mins after falling asleep.

REM sleeps lasts roughly 10 minutes the first time, increasing with each REM cycle. Rapid eye movement is so-called because the eyes quite literally move rapidly behind closed eyelids.

During REM, breathing becomes more rapid and irregular, heart rate and blood pressure increase to near waking levels. An interesting fact about REM sleep is that people experience less and less of it as they grow older.

One of the two main things that control sleep is the ensemble of physical, mental, and behavioral changes that follow a daily cycle called circadian rhythms. The term circadian comes from the Latin circa, meaning around and dies, meaning day.

Circadian rhythms respond to the light-darkness cycle and are genetically predetermined, at least in part, and dictated by so-called biological clocks proteins that interact within cells in every tissue and organ in the human body.

The suprachiasmatic nucleus, a structure in the brain formed by a group of about 20,000 neurons, or nerve cells, coordinates all the biological clocks.

Secondly, the sleep-wake homeostasis also tracks a persons need for sleep and dictates when they get sleepy. The so-called homeostatic sleep drive increases with the time that a person spends being awake. Its visible effects on brain activity and connectivity between neurons have been well documented.

Another area that has been the focus of much research is the relationship between sleep and learning or memory formation. Scientists know for sure that sleep is crucial for learning but which stage of sleep is more important?

Does learning occur in the light REM sleep stage or the deep, non-REM phase of sleep? How do neurons in different brain areas coordinate across sleep stages to facilitate learning and memory consolidation?

Two studies that Medical News Today reported on help to shed light on these questions.

In the first study, the experimenters tampered with the study participants deep, non-REM sleep stage after asking them to learn a new set of movements. The scientists monitored the participants brain activity their motor cortex, specifically throughout the study.

The team led by Switzerland-based scientists found that a restless deep sleep resulted in a visibly reduced learning efficiency. The researchers explained that their results hinged on the brains synapses and their roles in learning.

Synapses are microscopic connections between neurons that, together with brain chemicals, or neurotransmitters, facilitate the passing of electrical impulses from one neuron to another. During the day, synapses switch on in response to the stimuli that the brain receives from the environment.

But during sleep, the activity of these synapses goes back to normal. Without this restorative period, they stay excited at their peak activity for too long.

This interferes with the brains neuroplasticity that is, its ability to re-wire itself and create new connections between neurons. Neuroplasticity enables the brain to pick up new skills, change and adapt to its environment stimuli, and ultimately learn new things.

Nicole Wenderoth, a professor in the Department of Health Sciences and Technology at the ETH Zurich, and co-lead author explains what occurred in their new study.

In the strongly excited region of the brain, learning efficiency was saturated and could no longer be changed, which inhibited the learning of motor skills.

To the authors knowledge, this was the first study that showed a causal relationship between the deep phase of sleep and learning efficiency. We have developed a method that lets us reduce the sleep depth in a certain part of the brain and therefore prove the causal connection between deep sleep and learning efficiency, says study co-author Prof. Reto Huber.

The second study that MNT reported on looked at different sleep stages. However, this research showed that sleep does not just enable the brain to learn new things but also unlearn.

The original 2017 study involved an auditory learning task. The researchers played sound sequences while the participants were asleep and awake.

They monitored the volunteers brain electrical activity using an electroencephalogram (EEG).

The EEGs also captured sleep spindles that occurred when the sleeping brain learned new sounds. Sleep spindles are spikes in oscillatory brain activity that previous research has linked with learning and memory consolidation.

After each sleep session, the experimenters asked the participants to re-listen to the sound sequences and recognize them. They assessed their learning performance through tests.

Using the EEG readings, the scientists examined three sleep phases: REM sleep, light non-REM sleep, and deep non-REM sleep.

When exposed to the sounds during REM sleep or during light non-REM sleep, the participants were better at recognizing them when awake. But, when exposed to the new sounds during deep non-REM sleep, they had a harder time recognizing the sound sequence during wakefulness.

Also, while EEG markers of learning were readily observed in light [non-REM] sleep, they were markedly absent in deep [non-REM] sleep, report the scientists.

Furthermore, and importantly, not only was it hard for the participants to recognize the sounds that the researchers had played to them in their deep non-REM sleep, but they also found it more difficult to (re)learn these sounds, compared with entirely new sounds.

The findings suggest that deep non-REM sleep is not so much to learn new things as it is to suppress information.

[The] biggest surprise came from the brains ability to unlearn. Thus, it seems that during sleep, we can either form new memories, learn, or do the reverse: suppress memories and unlearn.

Thomas Andrillon, study first author

They also add to the evidence that deep sleep helps maintain neuroplasticity. Specifically, light non-REM sleep (stage 2) may help excite synapses, while deep non-REM sleep may help them relax, or downscale.

Such a contrast between light [non-REM] and deep [non-REM] sleep is consistent with a qualitative distinction between these two sleep stages in relation to neural plasticity, write the authors. According to this view, light [non-REM] sleep favors synaptic potentiation, while deep [non-REM] sleep favors synaptic downscaling.

We do not suggest any functional role for the suppressive effect of information presented during sleep, they add. Rather, it seems an inevitable byproduct of the synaptic downscaling needed for homeostatic purposes.

In other words, deep sleep may help us unlearn or forget because forgetting is a natural byproduct of preserving neuroplasticity; forgetting is a byproduct of our ability to learn.

Andrillon and colleagues also explained that their findings are significant because they help unify two previously contradictory schools of thought. One sees sleeps primary function as learning and consolidating new information. The other sees it as discarding useless information so as not to overwhelm the brain.

As scientists gather more and more neuroscientific evidence about how sleep works, it becomes apparent that overall, such divisions and dichotomies are perhaps not the most useful way of looking at sleep or the role sleep has in learning.

For example, a study published only last month shows that REM and non-REM sleep work together to boost learning.

Namely, non-REM sleep boosts the performance of newly acquired skills by restoring flexibility and neuroplasticity, while REM sleep stabilizes these improvements and prevents new learning from erasing them.

The new research started from the same hypothesis that the studies above seem to highlight that sleep must strengthen the synapses and the neuronal connections created during the day (to solidify new knowledge and prevent it from being overwritten by new information). However, it must also downscale, or relax or weaken, the synapses to preserve their flexibility and the brains neuroplasticity.

This study led by Masako Tamaki, from the Department of Cognitive, Linguistic, and Psychological Sciences at Brown University in Providence, RI involved a visual learning task. The researchers assigned one group of participants two different tasks, one before sleep and one after sleep. The other group did not receive any learning tasks.

The scientists used MRI scanners and electrodes that they applied to the participants heads and eyelids. They also used magnetic resonance spectroscopy to measure the two brain chemicals involved in neural plasticity (or flexibility of the synapses) and stabilization.

Tamaki and team found that neuroplasticity increased during non-REM sleep. This had associations with better learning and task performance after sleep.

During REM sleep, the participants neural plasticity dropped, which correlated with the stabilization of what they had learned. The researchers hypothesize that REM sleep helps prevent learning before sleep from being overwritten by subsequent learning.

Unlike non-REM sleep, the researchers only saw the sharp fall in plasticity during REM sleep among the volunteers with a task to learn.

In the researchers words: The [neuroplasticity] increased during NREM [non-REM] sleep irrespective of whether pre-sleep learning occurred, but it was associated with post-sleep performance gains relative to pre-sleep performance. In contrast, the [neuroplasticity] decreased during REM sleep but only after pre-sleep training, and the decrease was associated with stabilization of pre-sleep learning.

These findings indicate that NREM sleep promotes plasticity, leading to performance gains independent of learning, while REM sleep decreases plasticity to stabilize learning in a learning-specific manner.

Masako Tamaki et al.

It is not just synapses that may help or hinder the learning process during sleep but also the neurons themselves. Some researchers have identified specific neurons with key roles in memory formation that help us actively forget dreams.

For instance, research appearing in the journal Science has located some of these neurons in the hippocampus, a brain area crucial for forming memories and learning.

Akihiro Yamanaka, Ph.D., from Nagoya University, Japan, and his colleagues experimented with some of these neurons that produce a melanin-concentrating hormone (MCH) that helps regulate both sleep and appetite.

Yamanaka and team conducted experiments in mice, which showed that the firing of this particular group of [MCH-producing] neurons during REM sleep controls whether the brain remembers new information after a good nights sleep.

Genetically deleting these neurons in mice suggested that these cells help the brain actively forget new, possibly unimportant information. What is more, the findings point to the role that these neurons have in forgetting dreams.

Co-lead author Thomas Kilduff, Ph.D., the director of the Center for Neuroscience at the SRI International research institute in Menlo Park, CA, explains.

Since dreams are thought to primarily occur during REM sleep, the sleep stage when the MCH cells turn on, activation of these cells may prevent the content of a dream from being stored in the hippocampus consequently, the dream is quickly forgotten.

The neuroscience of sleep helps explain how sleep helps us learn and forget. It also sheds light on sleeps pain-relieving and anti-anxiety effects.

For example, a study published last year found that a brain area associated with pain sensitivity (called the somatosensory cortex) is hyperactive in sleep-deprived participants. The findings suggested that not getting enough sleep interferes with the brains pain-processing neural circuits.

Additionally, the same study found that activity in the nucleus accumbens area of the brain had dropped after a sleepless night. The nucleus accumbens releases the neurotransmitter dopamine, which heightens feelings of pleasure and decreases sensations of pain.

Sleep loss not only amplifies the pain-sensing regions in the brain but blocks the natural analgesia centers, too, explains the senior study author Matthew Walker, a professor of neuroscience and psychology at the University of California in Berkeley.

The team also found that the brains insula, which evaluates pain signals and prepares the pain response, was also underactive in sleep-deprived people.

Sleeplessness interferes with this critical neural system that assesses and categorizes the pain signals and allows the bodys natural painkillers to come to the rescue, notes Adam Krause, the studys lead author.

As to the anxiolytic effects of sleep, functional MRI scans and polysomnograms have shown that the medial prefrontal cortex in the brain is key. This region deactivated after a sleepless night in some studies co-led by the same Prof. Walker.

Previous research suggests that the medial prefrontal cortex helps calm anxiety and reduce stress levels. In Prof. Walkers research, other regions associated with processing emotions were hyperactive in sleep-deprived patients.

Without sleep, Prof. Walker explains, its almost as if the brain is too heavy on the emotional accelerator pedal, without enough brake. A sleepless night caused anxiety levels to spike by up to 30% in their study, report the scientists.

Furthermore, the study found that anxiety levels dropped after a full night of sleep and that this decrease was even sharper in participants who spent more time in the deep non-REM stage of sleep.

Deep sleep had restored the brains prefrontal mechanism that regulates our emotions, lowering emotional and physiological reactivity, and preventing the escalation of anxiety.

Eti Ben Simon, study co-author

Link:
What happens in the brain when we sleep? - Medical News Today

WVU Rockefeller Neuroscience Institute expands pioneering Alzheimer’s treatment to wider region of the brain – DOTmed HealthCare Business News

A hospital nurse for 33 years, Nanette Miller would call her husband Frank at the end of each shift to let him know she was coming home. On Dec. 7, 2018, the phone call came with a somber declaration: I cant do this anymore.

Miller had to help on another hospital floor that day. She didnt know how to get back.

Several months later, she was diagnosed with what she and her husband had feared early onset Alzheimers disease.

Ad StatisticsTimes Displayed: 1079778Times Visited: 9495

Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.

Using focused ultrasound, Dr. Ali Rezai, executive chair of the RNI, and his team successfully opened the blood-brain barrier in a clinical trial with Miller, 54, of Mill Run, Pennsylvania.

By opening the blood-brain barrier, which separates the bloodstream from the brain tissue and restricts medicines, immunotherapy, gene therapy and other therapeutics from entering the brain, researchers hope it can reduce plaques and lessen Millers symptoms.

Rezai and his team previously made waves by being the first in the world to open the hippocampal blood-brain barrier in Alzheimers patients. With Miller, doctors took it a step further by targeting other parts of the brain, namely the parietal lobe, insula and precuneus.

Because our first trial with opening the blood-brain barrier was successful, we were able to treat larger parts of the brain, Rezai said. These other parts of the brain, broadly the parietal lobe, are involved in knowing where you are within your environment and surroundings, and in thinking and processing of memory.

During this study, doctors injected microscopic bubbles into the patients bloodstream, and exposed the bubbles to focused ultrasound from a treatment helmet attached to the MRI, temporarily causing the blood brain barrier to open.

The gradual decline

Forgetting how to return to her work floor was not the only memory setback for Miller. She struggled with number combinations to secure areas of the hospital containing medicines

A coconut cake she made mistakenly wound up in a cupboard. By the time, they found it, it had molded.

And, as an organist at Indian Creek Baptist Church in Mill Run for several years, Miller can no longer play the instrument.

According to the Mayo Clinic, Alzheimer's disease is a progressive disorder that causes brain cells to waste away and die. It is the most common cause of dementia a continuous decline in thinking, behavioral and social skills that disrupts a person's ability to function independently.

Here is the original post:
WVU Rockefeller Neuroscience Institute expands pioneering Alzheimer's treatment to wider region of the brain - DOTmed HealthCare Business News

Impact Of Covid-19 on Neuroscience Market 2020 Industry Challenges, Business Overview and Forecast Research Study 2026 – Owned

Overview for Neuroscience Market Helps in providing scope and definitions, Key Findings, Growth Drivers, and Various Dynamics.

The global Neuroscience market focuses on encompassing major statistical evidence for the Neuroscience industry as it offers our readers a value addition on guiding them in encountering the obstacles surrounding the market. A comprehensive addition of several factors such as global distribution, manufacturers, market size, and market factors that affect the global contributions are reported in the study. In addition the Neuroscience study also shifts its attention with an in-depth competitive landscape, defined growth opportunities, market share coupled with product type and applications, key companies responsible for the production, and utilized strategies are also marked.

This intelligence and 2026 forecasts Neuroscience industry report further exhibits a pattern of analyzing previous data sources gathered from reliable sources and sets a precedented growth trajectory for the Neuroscience market. The report also focuses on a comprehensive market revenue streams along with growth patterns, analytics focused on market trends, and the overall volume of the market.

Moreover, the Neuroscience report describes the market division based on various parameters and attributes that are based on geographical distribution, product types, applications, etc. The market segmentation clarifies further regional distribution for the Neuroscience market, business trends, potential revenue sources, and upcoming market opportunities.

Download PDF Sample of Neuroscience Market report @ https://hongchunresearch.com/request-a-sample/52793

Key players in the global Neuroscience market covered in Chapter 4:Xian Janssen Pharmaceutical Ltd.AstraZeneca plc.Qilu Pharmaceutical Co., Ltd.Huahai Pharmaceutical Co., Ltd.KRRPShandong Renhetang Pharmaceutical Co Ltd.Kanghong PharmaceuticalJiangsu Nhwa Pharmaceutical Co., Ltd

In Chapter 11 and 13.3, on the basis of types, the Neuroscience market from 2015 to 2026 is primarily split into:Anti-Parkinsons DrugsAlzheimer DiseasePsychotic DisordersEpileptic DisordersAutism Spectrum DisordersOthers

In Chapter 12 and 13.4, on the basis of applications, the Neuroscience market from 2015 to 2026 covers:HospitalsDiagnostic LaboratoriesResearch InstitutesOther

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:North America (Covered in Chapter 6 and 13)United StatesCanadaMexicoEurope (Covered in Chapter 7 and 13)GermanyUKFranceItalySpainRussiaOthersAsia-Pacific (Covered in Chapter 8 and 13)ChinaJapanSouth KoreaAustraliaIndiaSoutheast AsiaOthersMiddle East and Africa (Covered in Chapter 9 and 13)Saudi ArabiaUAEEgyptNigeriaSouth AfricaOthersSouth America (Covered in Chapter 10 and 13)BrazilArgentinaColumbiaChileOthers

The Neuroscience market study further highlights the segmentation of the Neuroscience industry on a global distribution. The report focuses on regions of North America, Europe, Asia, and the Rest of the World in terms of developing business trends, preferred market channels, investment feasibility, long term investments, and environmental analysis. The Neuroscience report also calls attention to investigate product capacity, product price, profit streams, supply to demand ratio, production and market growth rate, and a projected growth forecast.

In addition, the Neuroscience market study also covers several factors such as market status, key market trends, growth forecast, and growth opportunities. Furthermore, we analyze the challenges faced by the Neuroscience market in terms of global and regional basis. The study also encompasses a number of opportunities and emerging trends which are considered by considering their impact on the global scale in acquiring a majority of the market share.

The study encompasses a variety of analytical resources such as SWOT analysis and Porters Five Forces analysis coupled with primary and secondary research methodologies. It covers all the bases surrounding the Neuroscience industry as it explores the competitive nature of the market complete with a regional analysis.

Brief about Neuroscience Market Report with [emailprotected] https://hongchunresearch.com/report/neuroscience-market-52793

Some Point of Table of Content:

Chapter One: Report Overview

Chapter Two: Global Market Growth Trends

Chapter Three: Value Chain of Neuroscience Market

Chapter Four: Players Profiles

Chapter Five: Global Neuroscience Market Analysis by Regions

Chapter Six: North America Neuroscience Market Analysis by Countries

Chapter Seven: Europe Neuroscience Market Analysis by Countries

Chapter Eight: Asia-Pacific Neuroscience Market Analysis by Countries

Chapter Nine: Middle East and Africa Neuroscience Market Analysis by Countries

Chapter Ten: South America Neuroscience Market Analysis by Countries

Chapter Eleven: Global Neuroscience Market Segment by Types

Chapter Twelve: Global Neuroscience Market Segment by Applications12.1 Global Neuroscience Sales, Revenue and Market Share by Applications (2015-2020)12.1.1 Global Neuroscience Sales and Market Share by Applications (2015-2020)12.1.2 Global Neuroscience Revenue and Market Share by Applications (2015-2020)12.2 Hospitals Sales, Revenue and Growth Rate (2015-2020)12.3 Diagnostic Laboratories Sales, Revenue and Growth Rate (2015-2020)12.4 Research Institutes Sales, Revenue and Growth Rate (2015-2020)12.5 Other Sales, Revenue and Growth Rate (2015-2020)

Chapter Thirteen: Neuroscience Market Forecast by Regions (2020-2026) continued

Check [emailprotected] https://hongchunresearch.com/check-discount/52793

List of tablesList of Tables and FiguresTable Global Neuroscience Market Size Growth Rate by Type (2020-2026)Figure Global Neuroscience Market Share by Type in 2019 & 2026Figure Anti-Parkinsons Drugs FeaturesFigure Alzheimer Disease FeaturesFigure Psychotic Disorders FeaturesFigure Epileptic Disorders FeaturesFigure Autism Spectrum Disorders FeaturesFigure Others FeaturesTable Global Neuroscience Market Size Growth by Application (2020-2026)Figure Global Neuroscience Market Share by Application in 2019 & 2026Figure Hospitals DescriptionFigure Diagnostic Laboratories DescriptionFigure Research Institutes DescriptionFigure Other DescriptionFigure Global COVID-19 Status OverviewTable Influence of COVID-19 Outbreak on Neuroscience Industry DevelopmentTable SWOT AnalysisFigure Porters Five Forces AnalysisFigure Global Neuroscience Market Size and Growth Rate 2015-2026Table Industry NewsTable Industry PoliciesFigure Value Chain Status of NeuroscienceFigure Production Process of NeuroscienceFigure Manufacturing Cost Structure of NeuroscienceFigure Major Company Analysis (by Business Distribution Base, by Product Type)Table Downstream Major Customer Analysis (by Region)Table Xian Janssen Pharmaceutical Ltd. ProfileTable Xian Janssen Pharmaceutical Ltd. Production, Value, Price, Gross Margin 2015-2020Table AstraZeneca plc. ProfileTable AstraZeneca plc. Production, Value, Price, Gross Margin 2015-2020Table Qilu Pharmaceutical Co., Ltd. ProfileTable Qilu Pharmaceutical Co., Ltd. Production, Value, Price, Gross Margin 2015-2020Table Huahai Pharmaceutical Co., Ltd. ProfileTable Huahai Pharmaceutical Co., Ltd. Production, Value, Price, Gross Margin 2015-2020Table KRRP ProfileTable KRRP Production, Value, Price, Gross Margin 2015-2020Table Shandong Renhetang Pharmaceutical Co Ltd. ProfileTable Shandong Renhetang Pharmaceutical Co Ltd. Production, Value, Price, Gross Margin 2015-2020Table Kanghong Pharmaceutical ProfileTable Kanghong Pharmaceutical Production, Value, Price, Gross Margin 2015-2020Table Jiangsu Nhwa Pharmaceutical Co., Ltd ProfileTable Jiangsu Nhwa Pharmaceutical Co., Ltd Production, Value, Price, Gross Margin 2015-2020Figure Global Neuroscience Sales and Growth Rate (2015-2020)Figure Global Neuroscience Revenue ($) and Growth (2015-2020)Table Global Neuroscience Sales by Regions (2015-2020)Table Global Neuroscience Sales Market Share by Regions (2015-2020)Table Global Neuroscience Revenue ($) by Regions (2015-2020)Table Global Neuroscience Revenue Market Share by Regions (2015-2020)Table Global Neuroscience Revenue Market Share by Regions in 2015Table Global Neuroscience Revenue Market Share by Regions in 2019Figure North America Neuroscience Sales and Growth Rate (2015-2020)Figure Europe Neuroscience Sales and Growth Rate (2015-2020)Figure Asia-Pacific Neuroscience Sales and Growth Rate (2015-2020)Figure Middle East and Africa Neuroscience Sales and Growth Rate (2015-2020)Figure South America Neuroscience Sales and Growth Rate (2015-2020)Figure North America Neuroscience Revenue ($) and Growth (2015-2020)Table North America Neuroscience Sales by Countries (2015-2020)Table North America Neuroscience Sales Market Share by Countries (2015-2020)Figure North America Neuroscience Sales Market Share by Countries in 2015Figure North America Neuroscience Sales Market Share by Countries in 2019Table North America Neuroscience Revenue ($) by Countries (2015-2020)Table North America Neuroscience Revenue Market Share by Countries (2015-2020)Figure North America Neuroscience Revenue Market Share by Countries in 2015Figure North America Neuroscience Revenue Market Share by Countries in 2019Figure United States Neuroscience Sales and Growth Rate (2015-2020)Figure Canada Neuroscience Sales and Growth Rate (2015-2020)Figure Mexico Neuroscience Sales and Growth (2015-2020)Figure Europe Neuroscience Revenue ($) Growth (2015-2020)Table Europe Neuroscience Sales by Countries (2015-2020)Table Europe Neuroscience Sales Market Share by Countries (2015-2020)Figure Europe Neuroscience Sales Market Share by Countries in 2015Figure Europe Neuroscience Sales Market Share by Countries in 2019Table Europe Neuroscience Revenue ($) by Countries (2015-2020)Table Europe Neuroscience Revenue Market Share by Countries (2015-2020)Figure Europe Neuroscience Revenue Market Share by Countries in 2015Figure Europe Neuroscience Revenue Market Share by Countries in 2019Figure Germany Neuroscience Sales and Growth Rate (2015-2020)Figure UK Neuroscience Sales and Growth Rate (2015-2020)Figure France Neuroscience Sales and Growth Rate (2015-2020)Figure Italy Neuroscience Sales and Growth Rate (2015-2020)Figure Spain Neuroscience Sales and Growth Rate (2015-2020)Figure Russia Neuroscience Sales and Growth Rate (2015-2020)Figure Asia-Pacific Neuroscience Revenue ($) and Growth (2015-2020)Table Asia-Pacific Neuroscience Sales by Countries (2015-2020)Table Asia-Pacific Neuroscience Sales Market Share by Countries (2015-2020)Figure Asia-Pacific Neuroscience Sales Market Share by Countries in 2015Figure Asia-Pacific Neuroscience Sales Market Share by Countries in 2019Table Asia-Pacific Neuroscience Revenue ($) by Countries (2015-2020)Table Asia-Pacific Neuroscience Revenue Market Share by Countries (2015-2020)Figure Asia-Pacific Neuroscience Revenue Market Share by Countries in 2015Figure Asia-Pacific Neuroscience Revenue Market Share by Countries in 2019Figure China Neuroscience Sales and Growth Rate (2015-2020)Figure Japan Neuroscience Sales and Growth Rate (2015-2020)Figure South Korea Neuroscience Sales and Growth Rate (2015-2020)Figure Australia Neuroscience Sales and Growth Rate (2015-2020)Figure India Neuroscience Sales and Growth Rate (2015-2020)Figure Southeast Asia Neuroscience Sales and Growth Rate (2015-2020)Figure Middle East and Africa Neuroscience Revenue ($) and Growth (2015-2020) continued

About HongChun Research:HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details:Jennifer GrayManager Global Sales+ 852 8170 0792[emailprotected]

NOTE: Our report does take into account the impact of coronavirus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

The rest is here:
Impact Of Covid-19 on Neuroscience Market 2020 Industry Challenges, Business Overview and Forecast Research Study 2026 - Owned

These Scientists Just Completed a 3D ‘Google Earth’ for the Brain – Singularity Hub

Human brain maps are a dime a dozen these days. Maps that detail neurons in a certain region. Maps that draw out functional connections between those cells. Maps that dive deeper into gene expression. Or even meta-maps that combine all of the above.

But have you ever wondered: how well do those maps represent my brain? After all, no two brains are alike. And if were ever going to reverse-engineer the brain as a computer simulationas Europes Human Brain Project is trying to doshouldnt we ask whose brain theyre hoping to simulate?

Enter a new kind of map: the Julich-Brain, a probabilistic map of human brains that accounts for individual differences using a computational framework. Rather than generating a static PDF of a brain map, the Julich-Brain atlas is also dynamic, in that it continuously changes to incorporate more recent brain mapping results. So far, the map has data from over 24,000 thinly sliced sections from 23 postmortem brains covering most years of adulthood at the cellular level. But the atlas can also continuously adapt to progress in mapping technologies to aid brain modeling and simulation, and link to other atlases and alternatives.

In other words, rather than just another human brain map, the Julich-Brain atlas is its own neuromapping APIone that could unite previous brain-mapping efforts with more modern methods.

It is exciting to see how far the combination of brain research and digital technologies has progressed, said Dr. Katrin Amunts of the Institute of Neuroscience and Medicine at Research Centre Julich in Germany, who spearheaded the study.

The Julich-Brain atlas embraces traditional brain-mapping while also yanking the field into the 21st century.

First, the new atlas includes the brains cytoarchitecture, or how brain cells are organized. As brain maps go, these kinds of maps are the oldest and most fundamental. Rather than exploring how neurons talk to each other functionallywhich is all the rage these days with connectome mapscytoarchitecture maps draw out the physical arrangement of neurons.

Like a census, these maps literally capture how neurons are distributed in the brain, what they look like, and how they layer within and between different brain regions.

Because neurons arent packed together the same way between different brain regions, this provides a way to parse the brain into areas that can be further studied. When we say the brains memory center, the hippocampus, or the emotion center, the amygdala, these distinctions are based on cytoarchitectural maps.

Some may call this type of mapping boring. But cytoarchitecture maps form the very basis of any sort of neuroscience understanding. Like hand-drawn maps from early explorers sailing to the western hemisphere, these maps provide the brains geographical patterns from which we try to decipher functional connections. If brain regions are cities, then cytoarchitecture maps attempt to show trading or other functional activities that occur in the interlinking highways.

You mightve heard of the most common cytoarchitecture map used today: the Brodmann map from 1909 (yup, that old), which divided the brain into classical regions based on the cells morphology and location. The map, while impactful, wasnt able to account for brain differences between people. More recent brain-mapping technologies have allowed us to dig deeper into neuronal differences and divide the brain into more regions180 areas in the cortex alone, compared with 43 in the original Brodmann map.

The new study took inspiration from that age-old map and transformed it into a digital ecosystem.

Work began on the Julich-Brain atlas in the mid-1990s, with a little help from the crowd.

The preparation of human tissue and its microstructural mapping, analysis, and data processing is incredibly labor-intensive, the authors lamented, making it impossible to do for the whole brain at high resolution in just one lab. To build their Google Earth for the brain, the team hooked up with EBRAINS, a shared computing platform set up by the Human Brain Project to promote collaboration between neuroscience labs in the EU.

First, the team acquired MRI scans of 23 postmortem brains, sliced the brains into wafer-thin sections, and scanned and digitized them. They corrected distortions from the chopping using data from the MRI scans and then lined up neurons in consecutive sectionspicture putting together a 3D puzzleto reconstruct the whole brain. Overall, the team had to analyze 24,000 brain sections, which prompted them to build a computational management system for individual brain sectionsa win, because they could now track individual donor brains too.

Their method was quite clever. They first mapped their results to a brain template from a single person, called the MNI-Colin27 template. Because the reference brain was extremely detailed, this allowed the team to better figure out the location of brain cells and regions in a particular anatomical space.

However, MNI-Colin27s brain isnt your or my brainor any of the brains the team analyzed. To dilute any of Colins potential brain quirks, the team also mapped their dataset onto an average brain, dubbed the ICBM2009c (catchy, I know).

This step allowed the team to standardize their results with everything else from the Human Connectome Project and the UK Biobank, kind of like adding their Google Maps layer to the existing map. To highlight individual brain differences, the team overlaid their dataset on existing ones, and looked for differences in the cytoarchitecture.

Based on structure alone, the brains were both remarkably different and shockingly similar at the same time. For example, the cortexesthe outermost layer of the brainwere physically different across donor brains of different age and sex. The region especially divergent between people was Brocas region, which is traditionally linked to speech production. In contrast, parts of the visual cortex were almost identical between the brains.

Rather than relying on the brains visible landmarks, which can still differ between people, the probabilistic map is far more precise, the authors said.

Whats more, the map could also pool yet unmapped regions in the cortexabout 30 percent or sointo gap maps, providing neuroscientists with a better idea of what still needs to be understood.

New maps are continuously replacing gap maps with progress in mapping while the process is captured and documented Consequently, the atlas is not static but rather represents a living map, the authors said.

Thanks to its structurally-sound architecture down to individual cells, the atlas can contribute to brain modeling and simulation down the lineespecially for personalized brain models for neurological disorders such as seizures. Researchers can also use the framework for other species, and they can even incorporate new data-crunching processors into the workflow, such as mapping brain regions using artificial intelligence.

Fundamentally, the goal is to build shared resources to better understand the brain. [These atlases] help usand more and more researchers worldwideto better understand the complex organization of the brain and to jointly uncover how things are connected, the authors said.

Image credit: Richard Watts, PhD, University of Vermont and Fair Neuroimaging Lab, Oregon Health and Science University

Continued here:
These Scientists Just Completed a 3D 'Google Earth' for the Brain - Singularity Hub

Slow to adjust to the pandemic’s ‘new normal’? Don’t worry, your brain’s just learning new skills – The Conversation AU

As COVID-19 lockdowns were introduced, we all suddenly had to find new ways of doing things. Schooling shifted online, meetings moved to Zoom, workplaces brought in new measures and even social events have changed to minimise physical interactions.

Many of us have found it hard to adapt to these transformations in our lives. Our research into memory, learning, and decision-making suggests part of the reason is that, for our brains, the change didnt simply involve transferring existing skills to a new environment.

More often, our brains are in effect learning entirely new skills, such as how to conduct a meeting while your cat walks across your computer keyboard, or how to work while filtering out the sound of kids yelling in the garden.

However, our research may also offer some reassurance that in time we will come to terms with a new way of life.

Read more: How memories are formed and retrieved by the brain revealed in a new study

Our new research, published in Nature Neuroscience, offers some suggestions about why doing new things can initially be so difficult, especially in a new or changing environment, but gets easier over time. Our findings indicate our surroundings have a changing influence on our choices and actions over time, and our brains process them differently as well.

We taught rats how to perform new actions, such as pressing a lever for food, in one place. Next, we moved them to another room with different wallpaper, flooring, and odours.

We then asked them to perform the same actions to receive a reward, but they were no longer able to do so. It was as if the rats needed to recall all the details of the memory of learning the task to perform it correctly, including the seemingly irrelevant ones.

Things were different when we tested the rats again a week later. By this time they could make accurate choices in either environment.

We also found that if we inactivated the hippocampus, the part of the brain that encodes detailed memories of the environment, rats could no longer perform a task they had just learned. However, they could still accurately perform tasks they had learned some time ago.

Our findings suggest that with experience and time, theres a change in both the psychological mechanisms and the brain mechanisms of learning how to do new things and make choices.

While the hippocampus appears to be crucial for a brief period, it becomes less important as time goes on.

If even details that ultimately prove irrelevant are necessary for us to remember a new skill in the early stages of learning, this may help to explain why new behaviours can be so difficult to learn when our circumstances change. For our brains, working from home may be like learning a whole new job not just doing the same job in a new place.

But the good news is it gets easier. In the same way rats eventually adapt to a new environment, we humans can learn to work with Zoom calls and interrupting pets.

Read more: Depression damages parts of the brain, research concludes

These findings may also help us understand conditions in which the hippocampus is damaged, such as Alzheimers disease and other neurodegenerative disorders, as well as psychiatric disorders such as depression and substance abuse. In time, better understanding could lead to insight into how people with such diseases might regain some functionality.

The implications for humans do come with caveats, of course: our study was done in rats, not people. But if you have struggled to adapt to a new way of doing things during this pandemic, we hope that it is of some comfort to know you are not alone. Rats, too, struggle to learn how to do new things in new places but it does get easier over time.

Read the original post:
Slow to adjust to the pandemic's 'new normal'? Don't worry, your brain's just learning new skills - The Conversation AU

Dealing with a pandemic and helping UK’s first transgender parents: Shrewsbury fertility clinic boss looks back on whirlwind year – shropshirestar.com

The psychotherapist, who is chief executive of the National Fertility Society, opened the NFS Hub in Shrewsbury as a not for profit agency aiming to offer women and same-sex couples the chance to seek affordable treatment so they can start families of their own.

But during the Covid-19 outbreak, the Human Fertilisation and Embryology Authority which regulates Britains fertility industry ordered private and NHS clinics to stop treating patients who are in the middle of an IVF cycle by mid April.

All new treatments were also banned and more than 30 patients were put on hold at the Shrewsbury clinic, which offers treatments such as blood tests and scans.

Sandra, who also lives in Shrewsbury, said: "We were only able to do emergency cases but we did offer free counselling sessions by telephone and Skype.

"We are now back open. It was quite a few weeks ago and there are new safety measures.

"We've put up signage, do temperature checks, we've got hand sanitiser and staff are in PPE."

Although she had hoped to gain a licence for it to become an Intrauterine Insemination (IUI) fertility clinic that involves directly inserting sperm into a woman's womb those plans will have to be reassessed again next year because of the pandemic.

However, one way the clinic has helped to bring new life into the world is through its surrogacy service, which also launched last year and provides a platform for surrogates and intended parents to meet and match.

Hannah and Jake Graf were lucky enough to be introduced to their surrogate by Sandra who helped them throughout their journey to becoming Britain's first parents who are both transgender.

They have attracted national media attention and starred in a TV documentary after welcoming their first child, a baby girl named Millie, in April during the height of the pandemic.

"I saw Jake and Hannah on Lorraine and I contacted them through Facebook asking if I could help," Sandra said.

"We have a few surrogates, they have to fill out an application form and we do background checks.

"Laura Warke, a lovely lady in northern Ireland, had been with us for a few weeks and was a first time surrogate.

"I introduced them and we all met up in London. Afterwards, I was in regular contact all the way through their journey."

The couple, from London, used an unknown sperm donor who matched Hannah's description and Jake's eggs which had been frozen several years ago.

"They were very lucky in finding a surrogate as quickly as they did," said Sandra, who co-founded the NFS which has been running since 2017.

"For it to work first time, everything fell into place.

"They were so nervous. At the start I was speaking to them every few days.

"I supported Laura too, making sure she was okay with travelling and everything else.

"Laura had the baby in northern Ireland and Jake and Hannah went over to be there.

"It's enabled them to create the family they wanted. To be on this journey with them has been amazing.

"They knew becoming parents was going to be difficult. They'd also had quite a lot of negativity, messages saying they shouldn't be parents.

"For me different families come in different forms. The priority is the child."

The couple have since both thanked Sandra and the team at the National Fertility Society.

Hannah said: "Jake and I were super lucky to have our amazing surrogate Laura carry Millie for us, but that wouldn't have been possible if it weren't for the National Fertility Society who brought us together and guided us through our journey."

In a message of thanks, Laura also said the team had been at the end of the phone anytime she needed them, which "provided reassurance during a daunting time".

Sandra, who opened the NFS Hub in Yeomanry Road, Battlefield, with co-founder Joanne Carwardine, says going through an agency can ensure women and couples are not taken advantage of by potential surrogates who may try to charge large amounts of money in return for carrying a baby.

She added: "To come through an agency like us, everyone knows where they stand.

"There are people who want a lot of money for being a surrogate and you don't know who they are.

"We've had two babies born so far since setting up the surrogacy branch, with another due soon and one due next year."

For more information visit http://www.nationalfertilitysociety.co.uk

See more here:
Dealing with a pandemic and helping UK's first transgender parents: Shrewsbury fertility clinic boss looks back on whirlwind year - shropshirestar.com